| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 63.93▼ | 63.31▲ | 63.05▲ | 64.40▼ | 65.80▼ |
| MA10 | 63.73▲ | 62.85▲ | 63.19▲ | 65.38▼ | 56.53▲ |
| MA20 | 63.56▲ | 63.13▲ | 63.50▲ | 67.70▼ | 44.42▲ |
| MA50 | 62.94▲ | 64.03▼ | 65.23▼ | 55.44▲ | 29.85▲ |
| MA100 | 63.19▲ | 65.32▼ | 67.41▼ | 43.91▲ | N/A |
| MA200 | 63.47▲ | 67.52▼ | 66.16▼ | 32.97▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.028▲ | 0.152▲ | 0.094▲ | -1.531▼ | 2.132▲ |
| RSI | 57.939▲ | 55.518▲ | 49.409▼ | 50.897▲ | 75.729▲ |
| STOCH | 84.549▲ | 55.662 | 31.983 | 23.920 | 72.453 |
| WILL %R | -34.091 | -38.116 | -38.116 | -90.265▼ | -45.167 |
| CCI | 56.131 | 114.255▲ | 109.183▲ | -74.391 | 69.755 |
|
Thursday, May 14, 2026 02:12 AM
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated ...
|
|
Wednesday, May 13, 2026 01:32 PM
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
|
|
Wednesday, May 13, 2026 01:24 PM
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/05/26 | 63.36 | 65.50 | 61.63 | 63.90 | 1,082,667 |
| 13/05/26 | 64.56 | 65.00 | 62.1872 | 63.18 | 933,221 |
| 12/05/26 | 64.55 | 65.0679 | 62.96 | 64.65 | 1,013,754 |
| 11/05/26 | 65.02 | 67.7699 | 64.05 | 65.68 | 934,996 |
| 08/05/26 | 64.19 | 65.45 | 63.68 | 64.59 | 934,277 |
| 07/05/26 | 69.855 | 70.20 | 63.53 | 64.07 | 1,777,782 |
| 06/05/26 | 69.50 | 71.02 | 68.60 | 69.79 | 1,893,110 |
| 05/05/26 | 67.165 | 69.28 | 65.00 | 68.95 | 2,035,544 |
| 04/05/26 | 61.40 | 66.63 | 60.9773 | 66.46 | 2,183,233 |
| 01/05/26 | 68.75 | 69.25 | 62.08 | 62.58 | 3,944,120 |
|
|
||||
|
|
||||
|
|